These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 16168126)

  • 1. Celecoxib analogues disrupt Akt signaling, which is commonly activated in primary breast tumours.
    Kucab JE; Lee C; Chen CS; Zhu J; Gilks CB; Cheang M; Huntsman D; Yorida E; Emerman J; Pollak M; Dunn SE
    Breast Cancer Res; 2005; 7(5):R796-807. PubMed ID: 16168126
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-gastric cancer effects of celecoxib, a selective COX-2 inhibitor, through inhibition of Akt signaling.
    Kim N; Kim CH; Ahn DW; Lee KS; Cho SJ; Park JH; Lee MK; Kim JS; Jung HC; Song IS
    J Gastroenterol Hepatol; 2009 Mar; 24(3):480-7. PubMed ID: 18823436
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activated PI3K/Akt/COX-2 pathway induces resistance to radiation in human cervical cancer HeLa cells.
    Xia S; Zhao Y; Yu S; Zhang M
    Cancer Biother Radiopharm; 2010 Jun; 25(3):317-23. PubMed ID: 20578837
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Celecoxib modulates hypertrophic signalling and prevents load-induced cardiac dysfunction.
    Jacobshagen C; Grüber M; Teucher N; Schmidt AG; Unsöld BW; Toischer K; Nguyen VP; Maier LS; Kögler H; Hasenfuss G
    Eur J Heart Fail; 2008 Apr; 10(4):334-42. PubMed ID: 18343721
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanisms underlying the growth inhibitory effects of the cyclo-oxygenase-2 inhibitor celecoxib in human breast cancer cells.
    Basu GD; Pathangey LB; Tinder TL; Gendler SJ; Mukherjee P
    Breast Cancer Res; 2005; 7(4):R422-35. PubMed ID: 15987447
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Involvement of mitochondrial and Akt signaling pathways in augmented apoptosis induced by a combination of low doses of celecoxib and N-(4-hydroxyphenyl) retinamide in premalignant human bronchial epithelial cells.
    Schroeder CP; Kadara H; Lotan D; Woo JK; Lee HY; Hong WK; Lotan R
    Cancer Res; 2006 Oct; 66(19):9762-70. PubMed ID: 17018636
    [TBL] [Abstract][Full Text] [Related]  

  • 7. From the cyclooxygenase-2 inhibitor celecoxib to a novel class of 3-phosphoinositide-dependent protein kinase-1 inhibitors.
    Zhu J; Huang JW; Tseng PH; Yang YT; Fowble J; Shiau CW; Shaw YJ; Kulp SK; Chen CS
    Cancer Res; 2004 Jun; 64(12):4309-18. PubMed ID: 15205346
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The cyclooxygenase-2 inhibitor celecoxib blocks phosphorylation of Akt and induces apoptosis in human cholangiocarcinoma cells.
    Wu T; Leng J; Han C; Demetris AJ
    Mol Cancer Ther; 2004 Mar; 3(3):299-307. PubMed ID: 15026550
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glycine-extended gastrin inhibits apoptosis in colon cancer cells via separate activation of Akt and JNK pathways.
    Beales IL; Ogunwobi O
    Mol Cell Endocrinol; 2006 Mar; 247(1-2):140-9. PubMed ID: 16442704
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overcoming trastuzumab resistance in HER2-overexpressing breast cancer cells by using a novel celecoxib-derived phosphoinositide-dependent kinase-1 inhibitor.
    Tseng PH; Wang YC; Weng SC; Weng JR; Chen CS; Brueggemeier RW; Shapiro CL; Chen CY; Dunn SE; Pollak M; Chen CS
    Mol Pharmacol; 2006 Nov; 70(5):1534-41. PubMed ID: 16887935
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of either phosphatidylinositol 3-kinase/Akt or the mitogen/extracellular-regulated kinase, MEK/ERK, signaling pathways suppress growth of breast cancer cell lines, but MEK/ERK signaling is critical for cell survival.
    Ripple MO; Kalmadi S; Eastman A
    Breast Cancer Res Treat; 2005 Sep; 93(2):177-88. PubMed ID: 16187238
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Celecoxib, a cyclooxygenase-2 inhibitor, reduces neointimal hyperplasia through inhibition of Akt signaling.
    Yang HM; Kim HS; Park KW; You HJ; Jeon SI; Youn SW; Kim SH; Oh BH; Lee MM; Park YB; Walsh K
    Circulation; 2004 Jul; 110(3):301-8. PubMed ID: 15238462
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Celecoxib inhibits urokinase-type plasminogen activator (uPA) production in MDA-MB-231 breast cancer cells.
    Andrews HN; Habibi G; Kucab JE; Dunn SE
    Breast Cancer Res Treat; 2005 Nov; 94(1):47-52. PubMed ID: 16172791
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination of atorvastatin and celecoxib synergistically induces cell cycle arrest and apoptosis in colon cancer cells.
    Xiao H; Zhang Q; Lin Y; Reddy BS; Yang CS
    Int J Cancer; 2008 May; 122(9):2115-24. PubMed ID: 18172863
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The interplay between GRP78 expression and Akt activation in human colon cancer cells under celecoxib treatment.
    Tian S; Chang W; Du H; Bai J; Sun Z; Zhang Q; Wang H; Zhu G; Tao K; Long Y
    Anticancer Drugs; 2015 Oct; 26(9):964-73. PubMed ID: 26225471
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Using cyclooxygenase-2 inhibitors as molecular platforms to develop a new class of apoptosis-inducing agents.
    Zhu J; Song X; Lin HP; Young DC; Yan S; Marquez VE; Chen CS
    J Natl Cancer Inst; 2002 Dec; 94(23):1745-57. PubMed ID: 12464646
    [TBL] [Abstract][Full Text] [Related]  

  • 17. OSU-03012, a novel celecoxib derivative, is cytotoxic to myeloma cells and acts through multiple mechanisms.
    Zhang S; Suvannasankha A; Crean CD; White VL; Johnson A; Chen CS; Farag SS
    Clin Cancer Res; 2007 Aug; 13(16):4750-8. PubMed ID: 17699852
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synergistic apoptotic effect of celecoxib and luteolin on breast cancer cells.
    Jeon YW; Suh YJ
    Oncol Rep; 2013 Feb; 29(2):819-25. PubMed ID: 23229294
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synergistic tumoricidal effect between celecoxib and adenoviral-mediated delivery of mda-7 in human breast cancer cells.
    Suh YJ; Chada S; McKenzie T; Liu Y; Swisher SG; Lucci A; Hunt KK
    Surgery; 2005 Sep; 138(3):422-30. PubMed ID: 16213894
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PDK-1/AKT pathway as a novel therapeutic target in rhabdomyosarcoma cells using OSU-03012 compound.
    Cen L; Hsieh FC; Lin HJ; Chen CS; Qualman SJ; Lin J
    Br J Cancer; 2007 Sep; 97(6):785-91. PubMed ID: 17848913
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.